Aglaia Skolariki
Clinical Research Fellow
I am a medical oncology trainee, currently working as a Clinical Research Fellow in Oxford Cancer Trials Unit. I received my MD and MSc in Medical Research Methodology from the Aristotle University of Thessaloniki, Greece. I undertook my medical oncology training in Greece before moving to Oxford in 2021 to join Oxford Cancer Trials.
Following an Oncology Fellowship at Guy's Hospital in London, I pursued further MSc studies in Precision Cancer Medicine at the University of Oxford, supported by an Early Phase Cancer Trials Studentship. I have recently been awarded full funding for a DPhil in immuno-oncology as part of the CRUK Oxford Centre DPhil in Cancer Science Programme, starting in 2024.
My research focuses on understanding tumour-host interactions in the early stages of lung tumorigenesis for the development of novel preventative and therapeutic strategies.
Recent publications
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Journal article
Javed SR. et al, (2024), Br J Cancer, 131, 1724 - 1736
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.
Journal article
Skolariki A. et al, (2022), Explor Target Antitumor Ther, 3, 172 - 199
NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)
Conference paper
Coveler A. et al, (2022), ANNALS OF ONCOLOGY, 33, S697 - S698
NUC-7738 in patients with advanced solid tumours: Phase I results from the NuTide:701 phase I/II study
Conference paper
Symeonides SN. et al, (2022), ANNALS OF ONCOLOGY, 33, S745 - S746
PHASE 1 STUDY OF THE PORCUPINE (PORCN) INHIBITOR RXC004 IN COMBINATION WITH THE PD-1 INHIBITOR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Conference paper
Cook N. et al, (2022), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10, A752 - A752